

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/495	A1	(11) International Publication Number: WO 98/10764 (43) International Publication Date: 19 March 1998 (19.03.98)
<p>(21) International Application Number: PCT/EP97/04859</p> <p>(22) International Filing Date: 8 September 1997 (08.09.97)</p> <p>(30) Priority Data: 96870114 11 September 1996 (11.09.96) EP</p> <p>(34) Countries for which the regional or international application was filed: BE et al.</p> <p>(71) Applicant (for all designated States except US): UCB, S.A. [BE/BE]; Avenue Louise 326, B-1050 Bruxelles (BE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KÖNIG, Brigitte [DE/DE]; Boeingstrasse 21, D-58119 Hagen (DE). RIHOUX, Jean-Pierre [BE/BE]; Rue Haymont 17, B-5101 Erpent (BE). KÖNIG, Wolfgang [DE/DE]; Paul- Schürholzstrasse 1, D-45657 Recklinghausen (DE).</p> <p>(74) Agent: DUBOST, Thierry; UCB, S.A. - Dépt. D.T.B., Rue d'Anderlecht 33, B-1620 Drogenbos (BE).</p>		<p>(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: PHARMACEUTICAL COMPOSITION FOR TREATING VIRAL DISEASES</p> <p>(57) Abstract</p> <p>Use of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy-acetic acid, an individual optical isomer or a pharmaceutically acceptable salt thereof as an active ingredient for the production of a pharmaceutical composition for the treatment of diseases induced by the respiratory-syncytial-virus.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL DISEASES

The present invention is in the area of pharmaceutical compositions and methods of treatment of viral diseases in humans. More particularly the invention relates to pharmaceutical compositions for the treatment of diseases induced by the respiratory-syncytial virus (RSV).

It is well known that recurrent respiratory tract viral infections are followed by rapid sensitization to one or several antigens with increased levels of immunoglobulins E, see e.g. Oscar L. FRICK in J. Allergy Clin. Immunol. (November 1986), pp. 1013-1018. Further, one dominant virus causing wheezing in humans and more especially in children is respiratory syncytial virus. The latter is especially observed in children below 2 years of age in whom it causes bronchiolitis and pneumonia.

T. CHONMAITREE et al. In Journal of Infections Diseases, vol. 164 (3), pp. 592-594 (1991) discloses that mononuclear leukocytes from normal individuals produce a histamine-releasing factor (HRF) in response to exposure to respiratory viruses, suggesting that this cytokine may play a role in the mechanism of virus-induced bronchospasm. However these authors have also shown that this HRF appears to be distinct from most other cytokines such as interleukins-1-6, 8 and 9 or granulocytes.

R. C. WELLIVER et al. In New England Journal of Medicine vol. 305 (15), pp. 841-846 (1981) discloses that respiratory syncytial virus (RSV)-specific immunoglobulins E together with histamine are detectable in a majority of infants with various forms of respiratory illness due to RSV and showing wheezing. However a direct correlation of the titers of RSV-IgE with the quantity of histamine released could not be determined.

There are many theoretical mechanisms whereby viruses might induce or exacerbate an inflammation in the lower airways. In addition to alveolar macrophages, the peribronchiolar infiltration with neutrophilic granulocytes is observed after an infection with respiratory syncytial virus. Neutrophils are not only cells capable of phagocytosis and low molecular weight inflammatory mediator release, but they also have the potential to secrete multiple proinflammatory cytokines. Recently, new cytokines named chemokines were described as activating inflammatory cells, see for example Piotr KUNA in Pharmacia Allergy Research Foundation Award Book (1995) pp. 23-31. In this family of chemokines, interleukin-8 (IL-8) is a very potent chemotactic factor for polymorphonuclear cells. This chemokine, according to B. KÖNIG et al. in Journal of Leukocyte Biology (July 1996), is produced in high amounts by human polymorphonuclear cells during exposure to respiratory syncytial virus. In another study published by R. ARNOLD et al. in Immunology, 85, 364-372 (1995), evidence is presented that peripheral blood mononuclear cells synthesize and secrete the proinflammatory cytokine IL-8 following infection with the respiratory syncytial virus (RSV) even at low doses. The authors of this study suggest that the release of the potent chemotoxin IL-8 from

CONFIRMATION COPY

peripheral blood mononuclear cells might be responsible for the pronounced accumulation of polymorphonuclear granulocytes in the alveolar spaces during RSV-induced bronchiolitis.

H. P. HECKERT et al. In *Berliner Münchner Tierärztl Wschr.* Vol. 106 (7), pp. 230-235 (1993) discusses the treatment of Bovine RSV-infection. In addition to antibiotic therapy, the effect of treatment with the antihistamine diphenylhydramin was evaluated by measure of the internal body temperature. With the additional daily application of the antihistamine to the antibiotic therapy, the animals were significantly faster with fever. However the teaching of this document is strictly limited to bovines and, on the other hand, it fails to explain the respective mechanisms of action of each constituent of the prescribed combination.

From a therapeutic point of view, it must be pointed out that there is no specific treatment for curing respiratory syncytial virus infections. Moreover, it is well known that several drugs used for the treatment of allergy and asthma (corticosteroids, theophylline, ketotifen) display inhibiting effects on cells directly involved in the immune defense mechanisms, thereby increasing the risk of microbial and viral infections.

Thus an objective of the present invention is to provide useful pharmaceutical compositions for treating diseases induced by the respiratory-syncytial virus in humans.

The present invention is based on the unexpected recognition that 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, an individual optical isomer or a pharmaceutically acceptable salt thereof, displays a significant inhibiting effect on viral replication together with an inhibiting effect of RSV-induced cell modifications (IL-8 production). Moreover this pharmacological effect takes place without lowering the immune system of the patient.

This recognition demonstrates the existence of an unexpected protective effect obtained in treating diseases, such as acute bronchiolitis or viral pneumonia, induced by the respiratory syncytial virus in humans, by a method which comprises administering to a human in need of such therapy, a pharmaceutical composition comprising as an active ingredient, an effective amount of at least one compound selected from 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, an individual optical isomer or a pharmaceutically acceptable salt thereof.

The term "pharmaceutically acceptable salt" as used herein with respect to 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid means not only its addition salts with non-toxic organic and inorganic acids, such as acetic, citric, succinic, ascorbic, hydrochloric, hydrobromic, sulfuric, and phosphoric acids and the like, but also its metal salts (for example sodium or potassium salts), ammonium salts including quaternary ammonium salts and aminoacid salts.

The term "individual optical isomer" as used herein means the levorotatory and the dextrorotatory enantiomers thereof. As is well known in the art, purification of such enantiomers is a rather difficult process depending upon the selected way of preparation of the

compound and the optical purity of the starting material. Therefore the term "individual optical isomer" as used herein means that the said compound comprises at least 90%, preferably at least 95%, by weight of the said individual (either dextro- or levorotatory) optical isomer and at most 10%, preferably at most 5%, by weight of the other individual (respectively levo- or dextrorotatory) optical isomer. Each individual optical isomer may be obtained from its racemic mixture by using conventional means such as disclosed in British patent application No. 2,225,321. Additionally, each individual optical isomer can be prepared from the racemic mixture by enzymatic biocatalytic resolution, such as disclosed in U.S. Patents No. 4,800,162 and 5,057,427.

The most preferred active ingredients of the present invention are the racemate of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid and its dihydrochloride salt which is a histamine H₁ receptor antagonist well known as cetirizine dihydrochloride, and its levorotatory and dextrorotatory enantiomers.

For implementing the invention, the composition hereinabove described should contain an effective amount of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, a pharmaceutically acceptable salt or individual optical isomer thereof. An effective amount can be readily determined by the use of conventional techniques and by observing results obtained under analogous circumstance. In determining the effective amount, a number of factors are considered including, but not limited to: the species of patient; its size, age, and general health; the specific disease involved; the degree of or involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; and the use of concomitant medication.

An effective amount of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, its pharmaceutically acceptable salt or individual optical isomer thereof in the composition of the invention will generally vary from about 0.1 milligram per kilogram of body weight per day (mg/kg/day) to about 0.5 mg/kg/day. A posology (dose) of about 5 mg to about 50 mg, preferably once or twice per day, is preferred.

A composition according to the invention can be administered to a patient in any form or mode which makes the composition bioavailable in effective amounts, namely the oral route. For example, it can be administered orally, intranasally, or rectally. Oral administration is generally preferred. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the disease state to be treated, the stage of the disease, and other relevant circumstances.

The compositions of the invention can comprise 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, its pharmaceutically acceptable salt or individual optical isomer thereof alone or in combination with at least one

pharmaceutically acceptable carrier or excipient, the proportion and nature of which are determined by the solubility and chemical properties of the composition selected, the chosen route of administration, and standard pharmaceutical practice.

5 The carrier material may be a solid, semi-solid, or liquid material which can serve as a vehicle or medium for the active ingredient. Suitable carrier materials are well known in the art. The pharmaceutical compositions of the invention may be adapted for oral use and may be administered to the patient in the form of tablets, capsules, powders, elixirs, syrups, solutions, suspensions, or the like. The pharmaceutical composition of the invention may also be adapted for rectal use and may then be administered to the patient in the form of
10 suppositories.

The carrier material should be suitably selected with respect to the intended form of administration, and consistent with conventional pharmaceutical practice. For instance, for oral administration in the form of tablets or capsules, the therapeutically active drug components may be combined with any oral non-toxic pharmaceutically acceptable inert
15 carrier such as lactose or starch. Optionally, the pharmaceutical composition of the invention also contain a binder such as microcrystalline cellulose, gum tragacanth or gelatine, a disintegrating agent such as alginic acid, a lubricant such as magnesium stearate, a glidant such as colloidal silicon dioxide, a sweetening agent such as sucrose or saccharin, a coloring agent or a flavouring agent such as peppermint or methyl salicylate.

20 Because of their easy administration, tablets and capsules represent the most advantageous oral dosage unit form. If desired, tablets may be coated by standard aqueous or nonaqueous techniques with sugar, shellac or other entering coating agents. Desirably, each tablet or capsule contains from about 5 mg to about 50 mg of the active ingredient.

For the purpose of oral therapeutic administration, the compositions of the present
25 invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1% by weight of the active ingredient of the composition of the invention.

Such solutions or suspensions may also include one or more of the following adjuvants: a sterile diluent such as water for injection, physiologic saline solution, oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as
30 benzyl alcohol; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene diaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for adjusting of tonicity such as sodium chloride or dextrose. The preparation can be enclosed in ampoules, or multiple dose vials made of glass or plastic.

The invention is further defined by reference to the following examples describing in
35 detail the compositions of the present invention, as well as their utility.

While this invention has been described and illustrated with reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit of the

invention. For example, effective dosages other than the preferred ranges set forth hereinabove with respect to the active ingredients may be applicable as a consequence of variations of the responsiveness of the human treated, severity of symptoms, dosage related adverse effects, if any observed and similar considerations. Accordingly, such expected variations or differences in the practice of the present invention and the results obtained are contemplated in accordance with the objects and practices of the present invention.

Materials and Methods

Buffer

The buffer used for washing the polymorphonuclear cells consisted of 137 mM NaCl, 8 mM Na_2HPO_4 , 3 mM KCl, and 3 mM KH_2PO_4 , pH 7.4 (modified Dulbecco's phosphate-buffered saline). For stimulation assays the cells were suspended in RPMI 1640 medium (Gibco BRL, Eggenstein, Germany).

Preparation of polymorphonuclear (PMN) neutrophilic granulocytes

Human granulocytes were isolated from 200 ml of heparinized blood (15 U/ml) from healthy donors separated on a Ficoll-metrizoate gradient followed by dextran sedimentation and washed twice at 300 g. This method led to more than 95% pure PMN. The cells were diluted to a final density of 1×10^6 PMN.

Cell viability

Cell viability was studied by trypan blue exclusion, by analysis of lactate dehydrogenase (Boehringer, Mannheim, Germany), as well as by determination of mitochondrial activity using WST-1 (Boehringer, Mannheim, Germany) in stimulated and non-stimulated cells. The assays were performed as described by the manufacturer (Boehringer, Mannheim, Germany). All experiments were performed under conditions where the viability of the cell types in all three assays systems was greater than 80%.

Cell culture

Hep-2 epithelial cells, an epithelial tumor cell line, were obtained from the American Type Culture Collection as ATCC CCL 23 and were cultured at 37°C in 5% carbon dioxide in Dulbecco's modified eagle containing 5% heat-inactivated fetal bovine serum, 4mM L-glutamine and 80 µg/ml gentamicin. The cells were subcultured twice weekly.

Virus preparation

Virus preparation was performed as described by R. ARNOLD et al. in Immunology 82, 126-133 (1994). For crude preparation, respiratory syncycial virus (RSV), Long Strain (ATCC), was grown and titrated in HEP-2 cells. The RSV titre was determined in a plaque-forming unit

(PFU) assay. The stock titre of the virus pool used in the study was 5×10^6 PFU/ml. The stock solution was stored at -70°C until use. Interleukin-8 (IL-8) levels were under the detection limit in the stock solution, as analysed by enzyme-linked immuno sorbent assay (ELISA). The absence of mycoplasma infection was verified by microplasma-specific PCR.

5

Stimulation experiments

If not stated otherwise, human PMN (1×10^6 /ml) are treated with various amounts of RSV (10^3 - 10^7) plaque forming units [PFU] corresponding to a multiplicity of infection [m.o.i.] of 0.001 up to 10 in a volume of 1 ml RPMI-1640 medium for the indicated time intervals. The incubation was performed in the absence or in the presence of cetirizine dihydrochloride at the indicated concentrations. The cell supernatant of the stimulation experiments were collected by centrifugation and stored at -70°C until use for analysis. The cell supernatants were used for IL-8 determination; cell pellets were for RSV_{SH} genomic ribonucleic acid (RNA) detection.

IL-8 assay

PMN were suspended in RPMI medium at a concentration of 1×10^6 /ml. The cells were cultured in the presence of the appropriate stimulus for up to 24 hours. Culture supernatants were collected and analyzed for their IL-8 content. IL-8 release was determined using a sandwich ELISA according to the method indicated hereinbefore. In brief each well of a 96 well plate (Nunc Maxisorb, Roskilde, Denmark) was coated overnight at 4°C with 100 μl of buffer/polyoxyethylene sorbitan monolaurate (a product sold under the tradename TWEEN 20) (0.1%) containing anti IL-8 antibodies at a concentration of 5 $\mu\text{g}/\text{ml}$. The plates were washed three times with buffer/Tween, the appropriate samples of IL-8 standard (recombinant human IL-8; Calbiochem, Bad Soden, Germany) were added and incubation proceeded for 2 hours at 37°C . Thereafter, alkaline phosphatase-linked anti IL-8 antibody was added. After addition of p-nitrophenylphosphate (15 mg/ml) for quantification, an ELISA reader and for calculation Mikrotek software (SLT Labinstruments, Crailsheim, Germany) were used.

Analysis of genomic RSV-RNA

The analysis of RSV-specific genomic RNA was performed by coupled reverse transcription and polymerase chain reaction PCR detection of RSV-genomic-RNA encoding for the small hydrophobic protein (SH) of RSV as described previously by R. ARNOLD et al. in Immunology 82, 126-133 (1994). Total RNA from non-infected as well as from RSV-infected PMN (1×10^6 /ml) was extracted using Trizol (Gibco, Niedereggstein, Germany). Total RNA was dissolved in 30 μl H_2O . Expression of genomic RSV_{SH} RNA was analysed after reverse transcription with sense primers and PCR amplification of the cDNA transcripts. The reverse transcription step involved a reaction mixture (final volume 20 μl) containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 5 mM MgCl_2 , 1mM desoxynucleotides, 100 pM sense primers for RSV_{SH}.

10 U RNase inhibitor, 10 µl RNA sample and 200 U reverse transcriptase from Moloney-Murine-leukemia-virus (Gibco, Eggenstein, Germany). Reverse transcription reactions were performed at 37°C for 60 minutes. For PCR amplification of the cDNA products, reaction mixtures were mixed with 50 pM of sense and antisense primers and 2 U Taq Polymerase (Gibco, Eggenstein, Germany). The products of 20, 25, and 30 cycles (1 min, 94°C; 2 min, 53°C; 3 min, 72°C) were analysed on an agarose gel and visualised by ethidium bromide staining. The respective primers for RSV_{SH} were sense: 5'-ACCAATGGAAAATACATCC-3'; antisense: 5'-TGAATGCTATGTGTTG-3'. The predicted size of the amplified product was 204 base pairs for RSV_{SH} according to R. ARNOLD et al. already cited.

10

Statistical analysis

If not stated otherwise, all data show mean values of at least three individual experiments with cells from different donors.

15

Effects of cetirizine on RSV-specific mRNA synthesis

Recently, we have shown that RSV-specific genomic RNA resides inside PMNs up to 24 hours. We analyzed the effects of cetirizine on RSV-specific mRNA expression after stimulation of human PMN with RSV. Therefore, in a first set of experiments human PMN (1×10^6 /ml) were treated with RSV at a m.o.i. of 1-, 0.5-, 0.05-, 0.005-, for 2 hours as well as for 16 hours. The results of these experiments are shown in figure 1: Human PMN (1×10^6 /ml) were left untreated (lanes 1,2 and 7,8) or were treated with RSV (1 m.o.i.: lanes 3,9; 0.5 m.o.i.: lanes 4,10; 0.05 m.o.i.: lanes 5,11; 0.005 m.o.i.: lanes 6,12) for 2 hours (lanes 1-6) as well as for 16 hours (lanes 7-12) at 37°C. Cell pellets were analyzed for RSV-specific mRNA expression of the SH gene. The arrow indicates the amplified PCR product. M: 123 base pairs ladder (Gibco BRL, Eggenstein, Germany). Figure 1 shows that RSV-specific mRNA increases inside PMN with prolonged incubation time.

25

Next, human PMN (1×10^6 /ml) were treated with RSV at a m.o.i. of 1 in the absence or in the presence of cetirizine. The results of these experiments are shown in figure 2: human PMN were left untreated (lane 1) or were treated with RSV (1 m.o.i.) in the absence (lane 2) or in the presence of cetirizine (lanes 3-7; 100-, 10-, 1-, 0.1-, 0.01 µg/ 10^6 PMN). Incubation proceeded for 2 hours (Fig. 2A) as well as for 16 hours (Fig. 2B) at 37°C. The cell pellets were analyzed for RSV-specific mRNA of the RSV-SH-gene by RT-PCR. The arrow indicates the amplified product of the appropriate size. M: 123 base pairs ladder (Gibco BRL, Eggenstein, Germany). Figure 2 shows that the addition of cetirizine inhibits RSV-specific mRNA expression of the small hydrophobic (SH) gene. A decrease in RSV-specific mRNA expression was observed over the whole concentration range of cetirizine. Moreover a decrease in RSV-specific mRNA is indicative for a decrease in replicative virus. It should be noticed that such viral replication inhibition by an antihistamine was never observed before.

35

Effects of cetirizine dihydrochloride on RSV-induced IL-8 release from human PMN

Human PMN (1×10^6 /ml) were treated with RSV at a multiplicity of infection (m.o.i.) of 1 in the absence or in the presence of cetirizine dihydrochloride (100-, 10-, 1-, 0.1-, 0.01 μ g/ml) for a total incubation time of 2 hours at 37°C. As control, cells were treated with cetirizine (100-, 10-, 1-, 0.1-, 0.01- μ g/ml) or without cetirizine, in the absence of RSV (buffer control). Cell supernatants were analyzed for IL-8 release by ELISA. The results of these experiments are shown in figure 3: data present mean and standard deviation values from 8 independent experiments. Figure 3 shows that cetirizine dihydrochloride (hereinafter "cetirizine") down-regulated the RSV-induced IL-8 release. However, the effects of cetirizine were dose-dependent. In this regard, cetirizine at concentrations $> 0.01 \mu$ g/ml but $< 100 \mu$ g/ml led to a significant reduction in RSV-induced IL-8 release. Similar results were obtained after an incubation time up to 24 hours as well as at RSV concentrations up to 5 m.o.i. It should be noticed that such interference between an antihistamine and an IL-8 induction by RSV was never observed before.

Effects of cetirizine on the ongoing IL-8 release induced by RSV

Further experiments were performed to analyze the effects of cetirizine on an ongoing IL-8 release induced by RSV. Therefore, human PMN (1×10^6 /ml) were treated with RSV (1 m.o.i.) and cetirizine (100 μ g, 10 μ g, 1 μ g, 0.1 μ g, 0.01 μ g). Cetirizine was either added immediately (FIG. 4A), or 30 minutes (Fig. 4B), or 60 minutes (Fig. 4C), or 90 minutes (Fig. 4D) after onset of RSV treatment; a total incubation time of 2 hours at 37°C was chosen. Cell supernatants were analyzed for IL-8 release by ELISA. Our data show that cetirizine down regulates an ongoing IL-8 release by RSV. However, the most pronounced effects were observed when cetirizine was added at the onset of RSV treatment. Down regulation of RSV-induced IL-8 release was most pronounced at cetirizine concentrations $> 0.01 \mu$ g/ml and $< 10 \mu$ g/ml.

CLAIMS

1. Use of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, an individual optical isomer or a pharmaceutically acceptable salt thereof as an active ingredient for the production of a pharmaceutical composition for the treatment of diseases induced by the respiratory-syncytial-virus.
2. Use according to claim 1, wherein the pharmaceutical composition is in the form of a dose containing from 5 mg to 50 mg of the active ingredient.
3. Use according to claim 1, wherein the disease to be treated is selected from acute bronchiolitis and viral pneumonia.
4. Use according to claim 1, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier or excipient.
5. Use according to any of claims 1 to 4, wherein the pharmaceutical composition is in a form suitable for oral use.
6. Use according to claim 5, wherein the pharmaceutical composition is in the form of tablets, capsules, powders, elixirs, syrups, solutions or suspensions.
7. Use according to any of claims 1 to 4, wherein the pharmaceutical composition is in a form suitable for rectal use.
8. Use according to claim 7, wherein the pharmaceutical composition is in the form of suppositories.
9. Use according to claim 6, wherein the pharmaceutical composition is in the form of a solution or suspension containing at least 0.1% by weight of the active ingredient.
10. A pharmaceutical composition for the treatment of diseases induced by the respiratory-syncytial-virus containing 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, an individual optical isomer or a pharmaceutically acceptable salt thereof as active ingredient together with a pharmaceutically acceptable carrier.

1/4

Fig. 1






Fig. 2



A)



B)



2/4

Fig. 3Fig. 4 A

3/4

Fig. 4 B






Fig. 4 C



4/4

Fig. 4 D



INTERNATIONAL SEARCH REPORT

Inter. .onal Application No

PCT/EP 97/04859

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/495

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ANDERSON, G.P. ET AL: "New drugs for asthma therapy" 1991, BIRKHAUSER, BASEL XP002025611 Bernheim, J. et al: Cetirizine: More than an antihistamine? see page 269 - page 293 ---	1-9
Y	WOOD, R.A. ET AL: "Atopic disease, Rhinitis and conjunctivitis, and Upper respiratory infections" CURRENT OPINION IN PEDIATRICS, vol. 7, 1995, pages 615-627, XP000614721 see page 619, right-hand column, paragraph 4 - page 620, left-hand column, paragraph 1 --- -/--	1-9

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

22 December 1997

Date of mailing of the international search report

16. 01. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Seegert, K

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/04859

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WELLIVER, R.C.: "The development of respiratory syncytial virus-specific igE and the release of histamine in nasopharyngeal secretions after infection" THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 305, no. 15, 1981, pages 841-846, XP000614514 see abstract</p> <p style="text-align: center;">---</p>	1-9
Y	<p>CHONMAITREE, T. ET AL: "Respiratory viruses induce production of histamine-releasing factor by mononuclear leukocytes: a possible role in the mechanism of virus-induced asthma" THE JOURNAL OF INFECTIOUS DISEASES, vol. 164, no. 3, 1991, pages 592-594, XP000650850 see abstract</p> <p style="text-align: center;">---</p>	1-9
Y	<p>HECKERT, H.P. ET AL: "Klinische Hinweise auf eine unterstützende Wirkung von Antihistaminika (Benadryl-parenteral) bei der Behandlung der RSV-Infektion des Kindes" BMTW (GERMANY), vol. 106, no. 7, 1993, pages 230-235, XP000614554 "Zusammenfassung" see page 234 - page 235</p> <p style="text-align: center;">-----</p>	1-9

THIS PAGE BLANK (USPTO)